NCT00292396 - Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Psoriasis

Interventions

DRUG

Anti IL-12 monoclonal antibody/ABT-874

Please see Arm Description for intervention description and details.

DRUG

placebo

12 doses

Trial Locations (24)

23507

Site Reference ID/Investigator# 3366, Norfolk

30022

Site Reference ID/Investigator# 3347, Alpharetta

37215

Site Reference ID/Investigator# 994, Nashville

45219

Site Reference ID/Investigator# 992, Cincinnati

46256

Site Reference ID/Investigator# 993, Indianapolis

60077

Site Reference ID/Investigator# 3348, Skokie

63117

Site Reference ID/Investigator# 3349, St Louis

77030

Site Reference ID/Investigator# 796, Houston

84132

Site Reference ID/Investigator# 2081, Salt Lake City

92123

Site Reference ID/Investigator# 3351, San Diego

97035

Site Reference ID/Investigator# 991, Lake Oswego

97223

Site Reference ID/Investigator# 3367, Portland

98101

Site Reference ID/Investigator# 989, Seattle

02114

Site Reference ID/Investigator# 990, Boston

02919

Site Reference ID/Investigator# 3346, Johnston

75246-1613

Site Reference ID/Investigator# 3350, Dallas

B3H 1Z4

Site Reference ID/Investigator# 3361, Halifax

H7S 2C6

Site Reference ID/Investigator# 985, Laval

N5X 2P1

Site Reference ID/Investigator# 987, London

H2K 4L5

Site Reference ID/Investigator# 3364, Montreal

P1B 3Z7

Site Reference ID/Investigator# 794, North Bay

G1V 4X7

Site Reference ID/Investigator# 988, Québec

N2J 1C4

Site Reference ID/Investigator# 795, Waterloo

N8W 1E6

Site Reference ID/Investigator# 3360, Windsor

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY